Epilepsy And Migraines

All in the Family: A Genetic Link Between Epilepsy and Migraine

New research reveals a shared genetic susceptibility to epilepsy and migraine. Findings published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), indicate that having a strong family history of seizure disorders increases the chance of having migraine with aura (MA). Medical evidence has established that migraine and epilepsy often co-occur in patients; this co-occurrence is called “comorbidity.” Previous studies have found that people with epilepsy are substantially more likely than the general population to have migraine headache. However, it is not clear whether that comorbidity results from a shared genetic cause.


FDA Panel Approves New Device For Treating Adults with Partial Seizures

The U.S. Food and Drug Administration (FDA) Neurological Devices Panel voted unanimously (11 to 0 with two abstentions) that the clinical benefits of the NeuroPace RNS System outweigh the risks of its use. NeuroPace is seeking approval for the RNS System for treating adults with partial onset seizures that have not been controlled with two or more antiepileptic medications. The final decision regarding approval of the device is made by the FDA.


FDA Announces New Drug Application for Review

The New Drug Application (NDA) resubmission for STEDESA® (eslicarbazepine acetate), an adjunctive therapy in the treatment of partial onset seizures in patients 18 years and older, has been accepted for review by the U.S. Food and Drug Administration (FDA), indicating that the application is sufficiently complete to permit a substantive review. "The epilepsy community is excited about the FDA's decision to review the NDA resubmission for STEDESA® (eslicarbazepine acetate)," said Dr. Joseph Sirven, Chair of the Epilepsy Foundation's Professional Advisory Board and Editor-in-Chief of epilepsy.com. "We are thankful that the FDA will consider the benefits of novel therapeutics such as STEDESA® in helping people with difficult to control epilepsy."


UCB announces positive results in a trial designed for the goal of a Monotherapy Indication for Vimpat (Lacosamide)

UCB announces positive results in a trial designed for the goal of a Monotherapy Indication for Vimpat (Lacosamide) March 7, 2013. This week UCB announced positive and exciting first results of a Phase III study designed to evaluate the efficacy and safety of conversion to Vimpat® (lacosamide) monotherapy in adult epilepsy patients with partial-onset seizures with or without secondary generalization


Contact Us

501-227-5061 Phone
501-227-5234 Fax
888-527-5061 Toll Free

#2 Lile Court Suite 100
Little Rock, Arkansas 72205

Little Rock Office Location